# Meiji Seika Pharma

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/meiji-seika-pharma
Canonical HTML page: https://getbiobrief.com/entity/meiji-seika-pharma

## Recent coverage (2 stories)

### Meiji Licenses JE Vaccine Tech to Serum Institute for 2027 Filing
2026-08-24 09:41:38 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Full story: https://getbiobrief.com/story/meiji-serum-je-vaccine-tech-transfer-bio

### Arcturus and Rigel Q4 Previews: mRNA Innovation vs. Oncology Commercialization
2026-03-02 22:54:15 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Full story: https://getbiobrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.